A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2011
At a glance
- Drugs Cediranib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 17 Jun 2011 Actual end date changed from Nov 2010 to Apr 2011 as reported by ClinicalTrials.gov.
- 10 Jun 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.